Cargando…

Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials

INTRODUCTION: Interleukin (IL)-23 inhibitors are a new class of biologics currently undergoing clinical trials for the treatment of moderate-to-severe psoriasis. Phase III studies of guselkumab, an IL-23 receptor monoclonal antibody, are currently underway. METHODS: We summarize the available phase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Mio, Lee, Katherine, Jeon, Caleb, Sekhon, Sahil, Afifi, Ladan, Yan, Di, Lee, Kristina, Bhutani, Tina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574739/ https://www.ncbi.nlm.nih.gov/pubmed/28639011 http://dx.doi.org/10.1007/s13555-017-0187-0

Ejemplares similares

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Sekhon, Sahil, et al.
Publicado: (2017)

Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities
por: Jeon, Caleb, et al.
Publicado: (2017)

Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab
por: Bartholomew, Erin, et al.
Publicado: (2023)

Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
por: Yang, Eric J, et al.
Publicado: (2019)

Frequency and Management of Sleep Disturbance in Adults with Atopic Dermatitis: A Systematic Review
por: Jeon, Caleb, et al.
Publicado: (2017)

Guselkumab for plaque psoriasis
Publicado: (2019)

A Pilot Study to Assess the Reliability of Digital Image-Based PASI Scores Across Patient Skin Tones and Provider Training Levels
por: Wu, David, et al.
Publicado: (2022)

Guselkumab for the treatment of psoriasis – evidence to date
por: Nogueira, Miguel, et al.
Publicado: (2019)

Recent advances in phototherapy for psoriasis
por: Nakamura, Mio, et al.
Publicado: (2016)

Eczematous eruption after guselkumab treatment for psoriasis
por: Reyn, Birgit, et al.
Publicado: (2019)

Arthritis Interception in Patients with Psoriasis Treated with Guselkumab
por: Zabotti, Alen, et al.
Publicado: (2021)

Delusional parasitosis secondary to severe iron deficiency anemia
por: Sekhon, Sahil, et al.
Publicado: (2017)

A Case of the Safety and Efficacy of Guselkumab in Psoriasis with Alcoholic Liver Cirrhosis
por: Nam, Hyun Min, et al.
Publicado: (2021)

Dietary Behaviors in Psoriasis: Patient-Reported Outcomes from a U.S. National Survey
por: Afifi, Ladan, et al.
Publicado: (2017)

Guselkumab for the treatment of severe refractory psoriasis in a pediatric patient
por: Kim, Sa Rang, et al.
Publicado: (2019)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
por: Light, Jeremy G, et al.
Publicado: (2021)

Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab
por: Chiang, Cheng-Ying, et al.
Publicado: (2021)

Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule()()
por: Abrouk, Michael, et al.
Publicado: (2017)

Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
por: Mastorino, Luca, et al.
Publicado: (2022)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

Combining biologic and phototherapy treatments for psoriasis: safety, efficacy, and patient acceptability
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule()
por: Abrouk, Michael, et al.
Publicado: (2016)

The Patient’s Guide to Psoriasis Treatment. Part 4: Goeckerman Therapy
por: Zhu, Tian Hao, et al.
Publicado: (2016)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
por: Ruggiero, Angelo, et al.
Publicado: (2022)

The Patient’s Guide to Psoriasis Treatment. Part 1: UVB Phototherapy
por: Singh, Rasnik K., et al.
Publicado: (2016)

The Patient’s Guide to Psoriasis Treatment. Part 3: Biologic Injectables
por: Abrouk, Michael, et al.
Publicado: (2016)

Guselkumab More Effectively Neutralizes Psoriasis-Associated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab
por: Campbell, Kim, et al.
Publicado: (2023)

Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry
por: Walsh, Jessica A., et al.
Publicado: (2021)

RNA-seq and flow-cytometry of conventional, scalp, and palmoplantar psoriasis reveal shared and distinct molecular pathways
por: Ahn, Richard, et al.
Publicado: (2018)

Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab
por: Wechter, Todd, et al.
Publicado: (2018)

The use of ustekinumab and guselkumab in a pediatric psoriasis patient with active hepatitis B infection
por: Song, Eingun James, et al.
Publicado: (2020)

Effectiveness and tolerability of guselkumab in patients with psoriasis: A longitudinal Belgian retrospective multicenter study
por: Ghislain, Pierre-Dominique, et al.
Publicado: (2021)

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
por: VAN MUIJEN, Marloes E., et al.
Publicado: (2022)

Efficacy of guselkumab compared with adalimumab for psoriasis: a meta-analysis of randomized controlled studies
por: Fu, Hongyi, et al.
Publicado: (2022)

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies
por: Armstrong, April W., et al.
Publicado: (2018)

The Patient’s Guide to Psoriasis Treatment. Part 2: PUVA Phototherapy
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bs17mcdm99j8lak7a16baa0rli